We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Multimode Microplate Reader Emphasizes Label-Free Detection Technology

By LabMedica International staff writers
Posted on 01 Feb 2011
Drug discovery researchers now have the opportunity to upgrade their instrumentation to incorporate a new microplate reader that performs both optical label-free and traditional labeled assays. More...


This latest generation "EnSpire Multimode Plate Reader” boasts hardware designed by PerkinElmer, Inc. (Waltham, MA, USA) that is coupled with Corning Life Sciences (Corning, NY, USA) label-free "Epic” technology.

The reader's compact benchtop design combines Corning‘s Epic optical label-free technology with a range of classical labeled technologies, including quad monochromator-based absorbance and fluorescence intensity, ultrasensitive luminescence and patented Alpha technology in multiwell plate formats. Typically, Alpha technology kits are bead-based assays, using microparticles coated with either DNA or protein in a format suitable for use with automated reagent handling systems. Each AlphaScreen or AlphaLISA assay contains two bead types: donor beads, and acceptor beads. Binding of molecules captured on the beads leads to an energy transfer from one bead to the other, ultimately producing a luminescent or fluorescent signal.

The instrument can accommodate a portfolio of EnSpire label-free microplates that includes 384-well cellular and biochemical microplates, and 96-well cellular microplates.

These high performance microplates with proprietary coatings for label-free detection enable a wide range of biochemical and cellular assays. Automated liquid handling ensures the accuracy and consistency of results throughout the assay development process, and integrated software allows users to initiate assay development and data analysis more easily and simply.

Dr. Richard M. Eglen, president, bio-discovery at PerkinElmer, Inc., said, "Label-free technology represents a potential game-changer in drug discovery innovation, by offering researchers a universal platform to observe cellular interactions and the effects of possible new drug compounds on cells. This is a major improvement over the use of traditional labeled assay methods alone, which rely on more indirect and time-consuming methods of observation.”

Related Links:
PerkinElmer, Inc.
Corning Life Sciences


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Thyroid Test
Anti-Thyroid EIA Test
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.